Beam Therapeutics Inc. Q2 Loss decreases, beats estimates

Beam Therapeutics Inc. (BEAM) reported Loss for second quarter that decreased from the same period last year and beat the Street estimates.

The company's bottom line totaled -$71.95 million, or -$1.02 per share. This compares with -$76.25 million, or -$1.23 per share, in last year's second quarter.

Analysts on average had expected the company to earn -$1.08 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 277400% to $16.65 million from $0.006 million last year.

Beam Therapeutics Inc. earnings at a glance (GAAP) :

-Earnings (Q2): -$71.95 Mln. vs. -$76.25 Mln. last year.
-EPS (Q2): -$1.02 vs. -$1.23 last year.
-Analyst Estimates: -$1.08
-Revenue (Q2): $16.65 Mln vs. $0.006 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Follow RTT